Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
08/2003
08/28/2003WO2003070921A1 METHODS FOR PRODUCING Ϝδ T CELLS
08/28/2003WO2003070918A2 Rna interference by modified short interfering nucleic acid
08/28/2003WO2003070914A2 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070911A2 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r)
08/28/2003WO2003070905A2 Electroporation methods for introducing bioactive agents into cells
08/28/2003WO2003070903A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070897A2 RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070886A2 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid
08/28/2003WO2003070764A1 Method for producing interferon
08/28/2003WO2003070761A1 Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
08/28/2003WO2003070754A1 Histone deacetylase inhibitors and process for producing the same
08/28/2003WO2003070752A2 Mhc-peptide complex binding ligands
08/28/2003WO2003070744A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070739A1 Partial and full agonists of a1 adenosine receptors
08/28/2003WO2003070730A1 Pyrrolopyrimidine derivative
08/28/2003WO2003070729A1 Pyrrolopyrimidine derivatives
08/28/2003WO2003070726A1 Pyranones useful as atm inhibitors
08/28/2003WO2003070711A1 Oxa- and thiadiazoles and their use as metalloproteinase inhibitors
08/28/2003WO2003070709A1 Novel phenylalanine derivative
08/28/2003WO2003070707A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
08/28/2003WO2003070701A2 Syntheses of quinazolinones
08/28/2003WO2003070691A1 N-hydroxycarboxamide derivative
08/28/2003WO2003070686A1 Substituted phenylalkanoic acid derivative and use thereof
08/28/2003WO2003070264A1 Anion exchange resin adsorbed fraction, immunopotentiator and promoter for recovery from loaded stress originating in matsutake mushroom
08/28/2003WO2003070262A1 Pharmacological composition based on biologically active substances obtained from tribulus terrestris l
08/28/2003WO2003070261A1 Pharmacological substance from the plant tribulus terrestris
08/28/2003WO2003070252A1 Antipruritics
08/28/2003WO2003070242A1 Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases
08/28/2003WO2003070236A2 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
08/28/2003WO2003070235A1 Medicinal compositions for inhibiting tryptase
08/28/2003WO2003070220A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same
08/28/2003WO2003070219A1 Drug delivery system for the subconjunctival administration of fine grains
08/28/2003WO2003070192A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003WO2003070190A2 Surrogate antibodies and methods of preparation and use thereof
08/28/2003WO2003070188A2 Method of treating trx mediated diseases
08/28/2003WO2003070182A2 Sodium channel blockers
08/28/2003WO2003070166A2 Novel tyloindicines and related processes, pharmaceutical compositions and methods
08/28/2003WO2003069997A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
08/28/2003WO2003055911A3 Cystine-knot fold protein
08/28/2003WO2003053158A3 Malleable protein matrix and uses thereof
08/28/2003WO2003045364A3 Use of quinazolines to treat t-cell mediated diseases
08/28/2003WO2003037384A3 Polymer conjugates of protein kinase c inhibitors
08/28/2003WO2003031447A3 Pyrimidine derivatives
08/28/2003WO2003029289A3 Fragements of heat shock proteins and their use
08/28/2003WO2003025015A3 A soluble toll-like receptor
08/28/2003WO2003016335A3 Irreversible cysteine protease inhibitors of legumain
08/28/2003WO2003013434A3 Methods and compositions for treating diseases associated with excesses in ace
08/28/2003WO2002097044A3 Alternative splice forms of proteins as basis for multiple therapeutic modalities
08/28/2003WO2002094192A3 Antibodies against tumor necrosis factor delta (april)
08/28/2003WO2002083720A3 Intermediates and enzymes of the non-mevalonate isoprenoid pathway
08/28/2003WO2002081521A3 Osteoprotegerin in milk
08/28/2003WO2002074783A3 Modified interferon beta with reduced immunogenicity
08/28/2003WO2002072534A3 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
08/28/2003WO2002046749A3 Screening method for identifying compounds that selectively induce interferon alpha
08/28/2003WO2002041880A3 Use of pyrazolo[4,3-d]pyrimidines
08/28/2003WO2002036627A3 Interferons, uses and compositions related thereto
08/28/2003WO2002036149A3 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof
08/28/2003WO2002034940A3 Methods for screening compounds that modulate lipid metabolism
08/28/2003WO2002008399A3 Human kinases
08/28/2003WO2001095859A3 Novel heterocyclic analogs of diphenylethylene compounds
08/28/2003US20030162972 Pyridyl alkane acid amides as cytostatics and immunosupressives
08/28/2003US20030162968 1,4-Disubstituted benzo-fused urea compounds
08/28/2003US20030162964 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
08/28/2003US20030162954 Antitumor agents; gastrointestinal disorders
08/28/2003US20030162811 Heterocyclic amines such as 4-(3'-Thienyl)-alpha, alpha, 1-trimethyl-4-piperidinemethanol and/or prodrugs, used as analgesics for prophylaxis of neuropathic pain
08/28/2003US20030162808 Acetindine derivatives, their preparation and medicaments containing them
08/28/2003US20030162802 Preferential enzyme inhibitors such as 2-((4-6-pyrimidinedion -2-yl)amino)-4-methyl-5-thiazolecarboxylic acid ethyl ester, used for prophylaxis of lymphocyte associated disorders
08/28/2003US20030162801 Tricyclic compounds and their uses
08/28/2003US20030162799 Squaric acid derivatives
08/28/2003US20030162798 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
08/28/2003US20030162794 Benzazole derivatives and their use as jnk modulators
08/28/2003US20030162786 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein
08/28/2003US20030162775 Heterocyclic substituted pyrazolones
08/28/2003US20030162767 Novel 1,3-dihydro-2h-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them
08/28/2003US20030162764 Pyrimidine A2b selective antagonist compounds, their synthesis and use
08/28/2003US20030162748 Comprises liposomes attached to prodrugs through phosphonate linkages; phospholipases; targets liver/spleen
08/28/2003US20030162738 Antigenic composition comprising a polycationic peptide and inosine and cytosine
08/28/2003US20030162709 Methods of generating multispecific, multivalent agents from VH and VL domains
08/28/2003US20030162300 Galactomannan-oligosaccharides and methods for the production and use thereof
08/28/2003US20030162263 Specific peptide of 6 to 40 amino acids and is capable of giving rise to antibodies which inhibit superantigen activity associated with HERV-K18 (human endogenous retrovirus) localized in intron 1 of CD48 gene on chromosome 1
08/28/2003US20030162252 Isolating cDNAs encoding novel G protein-coupled receptor proteins derived from human spleen
08/28/2003US20030162196 Isolation nucleic acids; genetic engineering; diagnosis, therapy, prevention hematopoietic, nervous system disorders
08/28/2003US20030162175 NK cell receptor polynucleotides, polypeptides, and antibodies
08/28/2003US20030161899 For prophylaxis of inhalation allergic reactions comprising mixture of saturated hydrocarbons having viscosity of greater than 6 mm2/s123n; treatment of atopic rhinitis in the form of "hayfever"
08/28/2003US20030161884 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
08/28/2003US20030161837 Crosslinking an immunoglobulin or fragment thereof with anN-hydroxyl-succinimide ester and a maleimide linked vis a polyethyleneoxide spacer and incubating with a polypeptide having a sulfhydryl group (an allergen or autoantigen)
08/28/2003US20030161834 Adjuvant compositions comprising a saponin and and an immunostimulatory oligonucleotide containing unmethylated CpG (a cytosine guanosine dinucleotide DNA motif); synergistic induction of antigen; anticarcinogenic agents
08/28/2003US20030161826 Therapy for autoimmune disease; central nervous system disorders
08/28/2003US20030161816 Systems and methods for treating patients with processed lipoaspirate cells
08/28/2003US20030161809 Complexes; drug delivery
08/28/2003US20030161797 Method of reducing and treating UVB-induced immunosuppression
08/28/2003CA2477191A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
08/28/2003CA2477117A1 Pyrrolopyrimidine derivative
08/28/2003CA2477116A1 Pyrrolopyrimidine derivatives
08/28/2003CA2477014A1 Rna interference mediated inhibition of tnf and tnf receptor superfamily gene expression using short interfering nucleic acid (sina)
08/28/2003CA2476935A1 Drug delivery system for subconjunctival administration of fine particles
08/28/2003CA2476854A1 Surrogate antibodies and methods of preparation and use thereof
08/28/2003CA2476822A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
08/28/2003CA2476764A1 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003CA2476625A1 Mhc-peptide complex binding ligands
1 ... 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 ... 1172